Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $13.8 million.

  • Syndax Pharmaceuticals' Accounts Payables rose 18227.85% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.8 million, marking a year-over-year increase of 18227.85%. This contributed to the annual value of $11.6 million for FY2024, which is 1671.52% up from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Accounts Payables stood at $13.8 million, which was up 18227.85% from $17.4 million recorded in Q2 2025.
  • Syndax Pharmaceuticals' Accounts Payables' 5-year high stood at $17.4 million during Q2 2025, with a 5-year trough of $3.6 million in Q2 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' median Accounts Payables value was $8.1 million (recorded in 2023), while the average stood at $8.4 million.
  • In the last 5 years, Syndax Pharmaceuticals' Accounts Payables plummeted by 2743.94% in 2021 and then soared by 18227.85% in 2025.
  • Over the past 5 years, Syndax Pharmaceuticals' Accounts Payables (Quarter) stood at $5.7 million in 2021, then dropped by 23.27% to $4.4 million in 2022, then soared by 128.99% to $10.0 million in 2023, then rose by 16.72% to $11.6 million in 2024, then increased by 18.92% to $13.8 million in 2025.
  • Its Accounts Payables was $13.8 million in Q3 2025, compared to $17.4 million in Q2 2025 and $10.0 million in Q1 2025.